Page 318 - Drug Class Review
P. 318
Page 189 of 205
Drug Effectiveness Review Project
Groups similar at baseline: No substantive differences between the groups
Primary Outcome Measures: Breslow-Day test assessing the homogeneity of ORs for the incidence of AE in RIV/placebo receiving and not receiving a concomitant medication No clinically significant pattern of increased incidence of AEs associated with RIV and concomitant medication use compared with placebo; 31 statistically significant ORs were not homogenous; 21 of these differences exhibited a higher incidence in the placebo group; in cases where higher incidence was observed for RIV (salicylates and diuretics) significant differences
Alzheimer classification: NR
pooled population 73.1 58 94 19.5 Secondary Outcome Measures: NR Timing of assessments: NR Health Outcome Measures: None Intermediate Outcome Measures: were attributed to placebo group differences
• •
Final Report Update 1 Authors: Grossberg et al. Year: 2000 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: (% white) Other germane population qualities: MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
